VBI-1901

**VBI-1901** is an investigational bivalent enveloped virus-like particle cancer vaccine developed by VBI Vaccines for glioblastoma. It presents two cytomegalovirus antigens, glycoprotein B and phosphoprotein 65, to induce CMV antigen-specific cellular and humoral immune responses against CMV-positive tumor cells. The program was evaluated principally in recurrent glioblastoma, including intradermal administration with granulocyte-macrophage colony-stimulating factor and separate clinical evaluation with GSK's AS01B adjuvant. VBI-1901 received FDA Fast Track and Orphan Drug designations for recurrent glioblastoma. The Phase 1/2 study registered as NCT03382977 is listed as terminated. ([vbivaccines.com](https://www.vbivaccines.com/press-releases/vbi-vaccines-presents-encouraging-early-tumor-response-data-from-randomized-controlled-phase-2b-study-of-vbi-1901-in-recurrent-glioblastoma/))

Other names

gB/pp65 eVLPsCMV gB/pp65 eVLPseVLP CMV gB-pp65 plus GM-CSFVBI-1901 vaccineVBI1901 vaccineVBI 1901 vaccine